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ABSTRACT
The use of levoﬂoxacin in critically ill patients has progressively increased since commercial marketing
of the drug in 1999, despite the fact that few studies have been designed to assess the use of levoﬂoxacin
in this population. Pharmacological characteristics, broad spectrum of activity, and tolerability account
for the high interest in the drug for the treatment of different infectious diseases, including ventilator-
associated pneumonia (VAP), and the recommendation of levoﬂoxacin in guidelines developed by a
number of scientiﬁc societies. According to pharmacokinetic–pharmacodynamic data, it seems
reasonable to assume that an increase in activity follows from a larger dose, so that 500 mg ⁄ 12 h is
adequate in patients with VAP. In critically ill patients with VAP, levoﬂoxacin monotherapy is indicated
for empirical treatment of patients with early onset pneumonia without risk factors for multiresistant
pathogens, and in combination therapy for late onset VAP or for patients at risk for multiresistant
pathogens. The use of levoﬂoxacin in combination therapy is supported by multiple reasons, including:
increased empirical coverage in infections with suspected intracellular pathogens; substitution for more
toxic antimicrobial agents (e.g., aminoglycosides) in patients with renal dysfunction and in those at risk
for renal insufﬁciency; and severity of systemic response to infection (septic shock) that justiﬁes multiple
treatment with better tolerated antibiotics. The availability of the oral formulation allows sequential
therapy, switching from the intravenous route to the oral route. Levoﬂoxacin is well tolerated by
critically ill patients, with few adverse events of mild to moderate severity.
Keywords Critical care, critically ill patient, levoﬂoxacin, nosocomial pneumonia, review, ventilator-
associated pneumonia
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INTRODUCTION
Treatment of pneumonia related to mechanical
ventilation (ventilator-associated pneumonia,
VAP), as for the treatment of most nosocomial
infections diagnosed in critically ill patients
admitted to the intensive care unit (ICU), should
be started promptly using antimicrobial agents
prescribed empirically, as soon as the infection is
suspected on clinical grounds and immediately
after samples from the lower respiratory tract
have been collected. Different studies have high-
lighted the importance of the selection of empi-
rical antibiotics [1–5]. Appropriate empirical
antibiotic treatment is associated with lower
morbidity and higher survival rates. In a recent
set of guidelines [6], levoﬂoxacin has been inclu-
ded for the ﬁrst time as one of the antimicrobial
agents recommended for use in monotherapy for
empirical treatment of early onset pneumonia in
mechanically ventilated patients without known
risk factors for the selection of multiresistant
pathogens. Levoﬂoxacin has also been included in
the combined antibiotic therapy for patients with
late onset VAP and for patients with pneumonia
in the presence of risk factors for multiresistant
pathogens (Fig. 1). This antibiotic has been selec-
ted for several reasons, including pharmacologi-
cal characteristics (spectrum of activity,
pharmacodynamics, adverse events proﬁle) and
clinical tolerability, allowing safe administration
of the drug in patients with renal failure or
haemodynamic instability.
Later, when the aetiology of pneumonia has
been established, and according to the clinical
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response, treatment should be modiﬁed accord-
ing to results of antibiotic susceptibility testing,
selecting the most effective and best-tolerated
drug with reduced spectrum of activity and
lower effect on the endogenous anaerobic intes-
tinal ﬂora. In the majority of cases, directed
treatment can be continued in monotherapy.
Combined treatment should only be maintained
in cases of polymicrobial infections, when Pseu-
domonas aeruginosa has been isolated, or in
patients with a protracted clinical course. In
these circumstances, levoﬂoxacin continues to be
a therapeutic option among various available
quinolones.
The present review describes the criteria used
for the selection of levoﬂoxacin as one of the
antimicrobial agents for treating VAP, new phar-
macokinetic–pharmacodynamic concepts that jus-
tify the choice of levoﬂoxacin, and current
evidence for the use of this drug.
RATIONALE FOR THE USE OF
LEVOFLOXACIN IN THE TREATMENT
OF VAP
Adequate broad spectrum of activity to cover
causative pathogens of VAP
Microorganisms responsible for VAP vary largely
in relation to the patient’s underlying disease,
previous use of antimicrobials, days on mechan-
ical ventilation before respiratory infection, and
the presence of epidemics or endemics for a
particular pathogen in the hospital or service
where the patient is hospitalised. VAP is caused
by more than one pathogen in approximately
25% of patients [7].
(a) Early onset VAP or patients without risk factors
for multidrug resistant pathogens. In early onset
pneumonia that develops during the ﬁrst 4 days
of mechanical ventilation in patients without
VAP
RECOMMENDATIONS FOR 
DIAGNOSIS
. Comprehensive medical history
. Chest radiograph
. Blood cultures
. Samples of lower respiratory tract
. Thoracocentesis (pleural effusion)
. Arterial oxygen saturation
SUSPECTED DIAGNOSIS
. New onset of fever
. Purulent sputum
. Leukocytosis
. New lung infiltrate
. Increase oxygen needs
EMPIRICAL ANTIBIOTIC THERAPY
EARLY ONSET
NO KNOWN RISK FACTORS FOR 
MULTIDRUG-RESISTANCE 
PATHOGENS
LATE ONSET
RISK FACTORS FOR MULTIDRUG-
RESISTANT PATHOGENS
RECOMMENDED ANTIBIOTICS
. Ceftriaxone
or
. Levofloxacin, Moxifloxacin, or 
Ciprofloxacin
or
. Ampicillin/sulbactam
or
. Ertapenem
RECOMMENDED ANTIBIOTICS
. Cefepime, Ceftazidime
or
. Imipenem, Meropenem
or
. Piperacillin-tazobactam
plus
. Ciprofloxacin, Levofloxacin
or 
. Amikacin, Gentamicin, Tobramycin
Plus
, Linezolid, Vancomycin
Fig. 1. Initial empirical antibiotic
therapy for ventilator-associated
pneumonia.
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previous antibiotic exposure and in the absence of
chronic underlying illnesses (diabetes mellitus,
chronic obstructive pulmonary disease, liver cir-
rhosis), primary endogenous ﬂora present in the
patient at the time of admission (methicillin-
sensitive Staphylococcus aureus [MSSA], Haemophi-
lus inﬂuenzae, Streptococcus pneumoniae, and
enterobacteria) are predominately responsible
for the respiratory infection. Early onset pneumo-
nias in patients with altered consciousness or in
the immediate postoperative period following
elective surgery are typical examples of this
group [8–11]. The antimicrobial activity of levoﬂ-
oxacin includes all microorganisms expected in
this clinical scenario [12,13].
(b) Late onset VAP or patients at risk for multidrug
resistant pathogens. Late onset pneumonia that
develops in patients previously admitted to the
hospital and previously using antibiotics for the
treatment or prophylaxis of infection, and ⁄ or
with chronic underlying conditions is mostly
due to secondary endogenous ﬂora (Gram-neg-
ative bacteria, especially P. aeruginosa, Acinetob-
acter baumannii, and Staph. aureus, often
methicillin-resistant) [11,14,15]. In general, path-
ogens most prevalent in the area in which the
patient has been admitted predominate in the
secondary endogenous ﬂora, so that knowledge
of the epidemiological map of the ICU allows
selection of the empirical antibiotic regimen
[16].
The use of a combination of antimicrobial
agents in the empirical treatment of late onset
VAP, including two or more drugs active
against possible causative pathogens, has not
been associated with a higher survival [17].
However, although this practice has been ques-
tioned [18], it is accepted according to most
therapeutic guidelines, particularly in cases in
which P. aeruginosa is suspected as the respon-
sible organism [6,19]. There are limited data
regarding the efﬁcacy of antibiotic monotherapy
for the treatment of P. aeruginosa pneumonia, but
it seems that this modality is associated with a
lower rate of microbiological eradication and ⁄ or
higher relapse [20]. For this reason, these cases
are treated with antibiotic combinations, inclu-
ding a b-lactam with antipseudomonal activity
together with aminoglycosides or quinolones.
Levoﬂoxacin is a potentially useful drug in this
situation [6].
Favourable pharmacokinetic indicators
Levoﬂoxacin is widely distributed throughout the
body, and penetrates well into most body tissues
and ﬂuids. The relation of drug concentrations in
lung tissue and sputum compared with those
observed in plasma is greater than one [21]. After
the administration of oral levoﬂoxacin, 500 or
750 mg once daily, signiﬁcantly higher steady-
state concentrations were achieved in epithelial
lining ﬂuid and alveolar macrophages compared
with ciproﬂoxacin, 500 mg twice daily [22], but
lower than azithromycin after intravenous admin-
istration [23]. In a recent study, the steady-state
plasma and epithelial lining ﬂuid concentrations
of intravenous levoﬂoxacin, 500 mg, administered
once or twice daily in critically ill patients with
severe community-acquired pneumonia were
determined [24]. The plasma and epithelial lining
ﬂuid peak concentrations of levoﬂoxacin were
12.6 and 11.9 mg ⁄L, respectively, in the 24 h
regimen and 19.7 and 17.8 mg ⁄L, respectively,
in the 12 h regimen, showing a pulmonary per-
centage penetration of > 100% in both groups. In
another study, pharmacokinetic disposition of
intravenous and oral levoﬂoxacin in critically ill
adults was characterised [25]. Pharmacokinetic
evaluations were performed in 28 patients receiv-
ing intravenous levoﬂoxacin. Ten of these patients
were subsequently switched to oral levoﬂoxacin
and underwent a second pharmacokinetic evalu-
ation during oral therapy. Maximum and mini-
mum serum concentrations (Cmax and Cmin) were
signiﬁcantly lower in the sequential treatment
group than after intravenous dosing, but ap-
peared to be adequate for most pathogens found
in critically ill patients with normal renal func-
tion. On the other hand, in-vitro studies have
shown that levoﬂoxacin penetrates actively in the
phagocytic cells, which may facilitate action
against intracellular microorganisms as well as
increase drug concentration in the infectious foci
through mechanisms of phagocytic release. After
exposure to 5 and 50 mg ⁄L of levoﬂoxacin, the
mean ratios between intracellular and extracellu-
lar concentrations in neutrophils were 8.8 and 9.8,
respectively [26].
Levoﬂoxacin pharmacokinetics are described
by a linear two-compartment open model with
ﬁrst-order elimination, with Cmax and the area
under the concentration-time curve (AUC) both
increasing linearly in a dose-proportional fashion
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[21]. Although pharmacokinetic studies of levo-
ﬂoxacin with 500 mg and 750 mg doses have
been carried out in healthy populations and in
patients with infectious diseases and ⁄ or renal
dysfunction [27–30], there is little information
on pharmacokinetics in critically ill patients
with haemodynamic instability, or in connec-
tion with concomitant use of inotropic drugs,
furosemide or manitol, or high distribution
volumes. In a study of ICU patients treated
for early onset VAP with intravenous levoﬂoxa-
cin, 500 mg twice daily, AUC over the 12-h
dosage interval was c. 30–40% lower than in
healthy volunteers, in relation to a high renal
excretion of unchanged drug and a shorter
elimination half-life [31,32]. Co-administered
drugs used to treat underlying diseases (dopa-
mine, furosemide, manitol) may account, at least
partially, for this enhanced elimination in crit-
ically ill patients. These variations should be
taken into account in clinical practice as they
justify the twice daily dosage in patients with
severe pneumonia and normal renal function
[31,32].
Excellent tolerability in patients with renal
failure or at risk for renal dysfunction
In a pharmacosurveillance study performed
3 years after commercialisation of levoﬂoxacin in
the United States, unexpected severe adverse
events requiring modiﬁcation of the technical
form of the product were not registered [33].
However, safety and tolerability data in the
special population of critically ill patients, in
which failure of one or more organs is common,
are lacking. Adverse events recorded in an obser-
vational study carried out in Spanish ICUs [34] in
patients treated with levoﬂoxacin at doses
between 500 and 1000 mg ⁄day were scarce, i.e.,
c. 12.5% and not necessarily attributed to the use
of levoﬂoxacin since all patients were given other
drugs, half of which were from other antibiotic
classes. No case of withdrawal or modiﬁcation of
the treatment regimen due to adverse events was
recorded. However, the identiﬁcation of heart
rhythm disturbances that required medical treat-
ment in 2% of patients should encourage close
monitoring to assess the relationship with levoﬂ-
oxacin [34], particularly in patients treated with
high doses of the drug. In a clinical trial conduc-
ted in healthy volunteers to assess the effect of
increasing doses of levoﬂoxacin on the QT and
QTc interval (500, 1000, and 1500 mg), small
increases in QTc were observed with the
1500 mg dose [35]. Single doses of 1000 mg of
levoﬂoxacin transiently increased heart rate with-
out affecting the uncorrected QT interval.
Favourable pharmacodynamic parameters
In experimental models with ﬂuoroquinolones,
pharmacodynamic indicators relating microbiolo-
gical and pharmacokinetic variables have shown
a correlation between Cmax ⁄MIC ratio and bacte-
ricidal effect, so that this class of antimicrobial
agent is classiﬁed as concentration-dependent
killing [36]. Pharmacodynamic studies of levoﬂ-
oxacin demonstrated that the clinical and micro-
biological outcome was predicted by the ratio of
peak plasma concentration to MIC (peak ⁄MIC
ratio) [37]. Assessments of the in-vitro activity of
two doses of levoﬂoxacin (500 mg every 12 and
24 h, and 750 mg daily dose) against P. aeruginosa
and Strep. pneumoniae strains showed an increase
in bactericidal activity in relation to higher peak
concentrations [38,39]. In patients with hospital-
acquired pneumonia the factors inﬂuencing the
probability of a good microbiological or clinical
outcome following the administration of an infu-
sion of levoﬂoxacin (total dose, 750 mg) was
studied [40]. For patients with P. aeruginosa or
methicillin-resistant Staph. aureus (MRSA), a sec-
ond drug was added. Mean Cmax of levoﬂoxacin
was 15.0 mg ⁄L and AUC 147.1 mg Æ h ⁄L. Multi-
variate logistic regression analysis demonstrated
that the achievement of an AUC ⁄MIC ratio of ‡87
had a signiﬁcant effect on eradication of the
pathogen [40].
The area under the inhibitory curve (AUIC) is a
relatively new indicator of efﬁcacy, mainly used
in studies of ﬂuoroquinolones. An in-vitro study
examined the relationship between concentration
and the bactericidal power of ﬂuoroquinolones, as
well as the impact on selection of resistance [41].
Strains of P. aeruginosa, Klebsiella pneumoniae,
Escherichia coli, and Staph. aureus were exposed
to changing drug concentrations, mimicking
human two-compartment pharmacokinetics. Peak
concentration to MIC ‡10 or AUIC >125 resulted
in optimisation of bactericidal activity and pre-
vention of bacterial regrowth. Based on studies in
animal models, AUIC values of at least 100 should
be achieved for maximum clinical and bacterio-
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logical efﬁcacy against Gram-negative and intra-
cellular pathogens [42]. It has been shown that
AUIC values > 40 are predictors of clinical and
bacteriological efﬁcacy in Gram-positive cocci
[43]. Pharmacodynamic analysis of the activity
of levoﬂoxacin against Strep. pneumoniae revealed
that, 99% of the time, hospitalised patients
achieve an AUC ⁄MIC >30. This indicates that
levoﬂoxacin will be very effective in treating
Strep. pneumoniae infections in the majority of
patients. In the study carried out in patients
admitted to the ICU with early onset VAP who
were treated with levoﬂoxacin (500 mg ⁄ 12 h), it
was shown that Cmax ⁄MIC ratio and the AUIC
were constantly above the threshold of efﬁcacy,
which indicates that this therapeutic regimen
ensures an optimal exposure to prevent both
clinical failure and the development of bacterial
resistance. However, in three of the patients a
sustained superinfection by pathogens intrinsic-
ally resistant to levoﬂoxacin was diagnosed
[31,32].
Development of resistance during treatment
Although therapeutic failures due to the devel-
opment of bacterial resistance during treatment
with levoﬂoxacin, in particular against Strep.
pneumoniae have been reported [45,46], the risk
is lower than with the use of ciproﬂoxacin. In a
dynamic in-vitro model, time-kill data for ciproﬂ-
oxacin, clinaﬂoxacin, grepaﬂoxacin, levoﬂoxacin,
moxiﬂoxacin, and trovaﬂoxacin against three
isolates of quinolone-susceptible Strep. pneumoniae
were generated [47]. The rank order of activity,
with respect to bactericidal effect, was ciproﬂoxa-
cin (least active) < levoﬂoxacin < grepaﬂoxacin,
trovaﬂoxacin < clinaﬂoxacin and moxiﬂoxacin
(most active), whereas the rank order with respect
to the selection of resistance was ciproﬂoxacin
(most likely) > grepaﬂoxacin, moxiﬂoxacin, and
trovaﬂoxacin > levoﬂoxacin > clinaﬂoxacin. The
ongoing TRUST (Tracking Resistance in the
United States Today) study, which began mon-
itoring antimicrobial resistance among respiratory
pathogens in 1996, routinely tracks resistance at
national and regional levels [48]. The 1999–2000
TRUST study analysed 9499 Strep. pneumoniae,
1934 H. inﬂuenzae, and 1108 Moxarella catarrhalis
isolates. Levoﬂoxacin resistance was 0.5% nation-
ally (regional range, 0.1–1.0%). Using data
derived from mice infected with the bacterium
P. aeruginosa and treated with a ﬂuoroquinolone
antibiotic, a mathematical model was developed
to describe relationships between antimicrobial
drug exposure and changes in drug-susceptible
and -resistant bacterial subpopulations [49].
AUC ⁄MIC ratio of 157 : 1 was considered the
minimum threshold to suppress emergence of
resistance. Monte Carlo simulations were also
performed for 750 mg of levoﬂoxacin one daily
and ciproﬂoxacin 400 mg IV every 8 h; the overall
expected AUC ⁄MIC target attainment rate was
calculated to be 61.2% for levoﬂoxacin and 61.8%
for ciproﬂoxacin. These results do not favour the
use of this ﬂuoroquinolone in monotherapy for
the treatment of P. aeruginosa infection.
EVIDENCE FROM CLINICAL USE OF
LEVOFLOXACIN IN THE TREATMENT
OF VAP
Although multiple studies on the efﬁcacy and
tolerability of levoﬂoxacin in the treatment of
different infections, especially respiratory tract
infections, were conducted during the preclinical
phase [50–58] and with the marketed drug [59–
65], few studies have been carried out in patients
with VAP. Patients with VAP were only included
in two studies [31,32,64], the objectives of which,
however, were very different. One was a pros-
pective, noncomparative open study [31,32] that
included ten patients with early onset VAP
treated with levoﬂoxacin, 500 mg ⁄ 12 h. All
patients had normal renal function. The objective
of this study was to assess pharmacokinetic and
pharmacodynamic characteristics of levoﬂoxacin
in this patient population and the results obtained
have been described already. Clinical results
included in the study demonstrated the efﬁcacy
of levoﬂoxacin in patients with early onset VAP.
At the end of treatment, only eight patients
treated for a median of 8 days were evaluable.
The overall success rate was 75%, with eradica-
tion of the initial causative pathogen in all cases.
However, in three patients selection of levoﬂoxa-
cin-resistant microorganisms was observed
(A. baumannii in two, P. aeruginosa in one).
The goal of the second study [64] was to
compare the efﬁcacy and safety of levoﬂoxacin
750 mg and imipenem ⁄ cilastatin followed by
ciproﬂoxacin in adult patients with nosocomial
pneumonia, half of whom had VAP. This was a
multicentre, prospective, randomised, open-label
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trial conducted in North America. Patients were
randomly assigned to one of two treatment arms:
levoﬂoxacin 750 mg ⁄ 24 h given intravenously
initially and then orally for 7–15 days or imipe-
nem ⁄ cilastatin 500 mg to 1 g given intravenously
every 6–8 h, followed by oral ciproﬂoxacin
750 mg every 12 h for 7–15 days. Doses were
adjusted to renal function. Adjunctive antibacte-
rial therapy was mandatory in patients with
documented or suspected P. aeruginosa, including
ceftazidime 2 g ⁄ 8 h (or noncabapenem b-lactam)
in the levoﬂoxacin arm, or amikacin
7.5 mg ⁄ kg ⁄ 12 h (or an alternative aminoglyco-
side) in the imipenem ⁄ cilastatin arm. Vancomycin
was added to any of the groups in which MRSA
was suspected. The primary predeﬁned outcome
measure was the clinical response in microbio-
logically evaluable patients 3–15 days after the
end of therapy. The study enrolled 438 adult
patients (220 received levoﬂoxacin, and 218 imi-
penem ⁄ cilastin). Demographic and baseline clin-
ical characteristics were similar in the intent-to-
treat and clinically evaluable populations. In
patients evaluable for microbiological efﬁcacy,
clinical success (cure or improvement) was
achieved in 58.1% of patients who received
levoﬂoxacin, compared with 60.6% of patients
who received the comparator regimen [95%
conﬁdence interval (CI) )12.0 to 17.2]. Similar
clinical results were seen in patients evaluable for
clinical efﬁcacy and in the intent-to-treat popula-
tion. In the 187 patients evaluable for microbio-
logic efﬁcacy, eradication was achieved in 66.7%
of patients receiving levoﬂoxacin and 60.6% of
patients receiving imipenem ⁄ cilastin (95% CI,
)20.3 to 8.3). In this study, levoﬂoxacin was at
least as effective and was as well tolerated as
imipenem ⁄ cilastatin, followed by ciproﬂoxacin in
adult patients with nosocomial pneumonia, as
demonstrated by comparable clinical and micro-
biological success rates. These ﬁndings, however,
do not support the use of monotherapy with
levoﬂoxacin in patients with VAP since a high
percentage of patients were given combined
regimens because of suspected or conﬁrmed P.
aeruginosa infection [66].
In a subanalysis of the subgroup of patients
with VAP from the aforementioned multicentre,
prospective, randomised trial comparing levoﬂ-
oxacin and imipenem ⁄ cilastatin [67], 222 patients
were included in the study cohort with half
(n ¼ 111) of the patients assigned to each treat-
ment group. The patients in both groups were
similar with respect to age, severity of illness
(APACHE II score 14.8 vs. 15.1), and duration of
mechanical ventilation before the onset of VAP
(7.8 vs. 9.8 days). The distribution of other mark-
ers of severity, including use of vasopressor drugs
(17.1% vs. 12.6%), pleural effusion (2.7% vs. 0%),
multilobar radiologic involvement (1.8% vs. 4.5),
bacteraemia (6.3% vs. 2.7%), or serum creatinine
concentration greater than 1.5 mg ⁄dL (8.1% vs.
12.6%) was similar in both arms. The study
groups were well balanced in regard to MRSA
isolates (10.8% vs. 9.9%), concomitant use of
vancomycin (11.7% vs. 9.9%), or administration
of empirical combinations of antibiotics for the
treatment of suspected P. aeruginosa pneumonia
(30.6% vs. 25.2%). The main pathogens treated in
the levoﬂoxacin group were MSSA (18 cases),
P. aeruginosa (16 cases), Serratia marcescens (13
cases), and H. inﬂuenzae (13 cases), whereas H.
inﬂuenzae (21 cases), MSSA (19 cases), P. aerugi-
nosa (18 cases), and Enterobacter cloacae (11 cases)
were the pathogens isolated in the imipenem ⁄ cil-
astin group. In ﬁve cases in each group, MRSA
was cultured. Among the intention-to-treat pop-
ulation, clinical success (between 3 and 15 days
after the end of treatment) was achieved in
58.6% of patients receiving levoﬂoxacin com-
pared with 63.1% of patients receiving imipe-
nem ⁄ cilastatin (95% CI, )8.77% to 17.79%).
Similar results were obtained in patients with
VAP caused by P. aeruginosa (87.5% vs. 61.1%,
p ¼ NS). Multivariate analysis demonstrated that
assignment to different antibiotic treatments (i.e.,
levoﬂoxacin vs. imipenem ⁄ cilastatin) was not
predictive of outcomes. The overall mortality
was lower than 15%. The frequency of adverse
events was similar (30.6% vs. 32.4%) and for
only four patients in the levoﬂoxacin group and
two patients in the imipenem group, treatment
was withdrawn because of adverse events. The
only difference between treatment arms identi-
ﬁed in the study was related to the development
of P. aeruginosa superinfection: ten patients in the
imipenem ⁄ cilastin group, compared with three
patients in the levoﬂoxacin group (p ¼ 0.045).
Results of this secondary analysis in a popula-
tion of patients with VAP suggests that levoﬂ-
oxacin and imipenem ⁄ cilastin are equivalent for
the treatment of one of the most frequent and
serious infections in patients admitted to the
ICU.
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These ﬁndings are similar to those reported for
ciproﬂoxacin in the management of nosocomial
pneumonia in prospective, randomised and com-
parative studies [20,68–70]. Imipenem was the
comparator drug in two studies [20,68],
ceftazidime in one, and the comparator treatment
was not standardised in another study [70]. The
efﬁcacy of quinolones and comparator antibiotics
was similar in the individual studies as well as in
a meta-analysis of all trials of quinolones for
treatment of nosocomial pneumonia, with a
pooled odds ratio for clinical cure of 1.12 (95%
CI, 0.80–1.55). In the studies in which data on
microbiological outcome was provided [20,64,68],
there was a lower tendency towards the emer-
gence of resistant pathogens especially P. aerugi-
nosa among levoﬂoxacin-treated patients.
Paradoxically, despite the small number of
studies in critically ill patients, a progressive
increase in the use of levoﬂoxacin in ICUs
throughout Spain has been observed. Levoﬂoxa-
cin was the 10th antimicrobial agent most fre-
quently prescribed in 2004, the 11th among those
used in patients with extra-ICU nosocomial infec-
tion, and the 13th among antibiotics used for the
treatment of ICU-acquired infection (annual
report ENVIN-UCI 2004, unpublished data).
In an observational study of the use of levoﬂ-
oxacin in critically ill patients, with the participa-
tion of 30 Spanish ICUs [34] and an analysis of 543
prescriptions of this drug, 32.2% of all indications
corresponded to treatment of nosocomial infec-
tions, especially those acquired in the ICU. In a
secondary analysis of data from this study,
focused on the use of levoﬂoxacin for the treat-
ment of pneumonia [72], 39 patients with
ICU-acquired pneumonia, most of them in rela-
tion to mechanical ventilation [87.2%], received
levoﬂoxacin. Combined antibiotic treatment was
administered to 25 patients and the response was
satisfactory in 78.3% of cases. Although the aim of
this descriptive study was not to assess the
effectiveness of levoﬂoxacin in VAP, data on the
use of this drug conﬁrm that levoﬂoxacin is an
alternative in this clinical situation.
CRITERIA TO BE CONSIDERED IN
CHOOSING LEVOFLOXACIN FOR
DIRECTED TREATMENT OF VAP
A large number of antimicrobial agents evaluated
in clinical trials have been approved by the
regulatory agencies for use in the treatment of
VAP. The choice of one of these drugs in daily
practice depends on different factors, such as:
inclusion in therapeutic guidelines recommended
by prestigious scientiﬁc societies [6,19]; character-
istics of the individual patients with VAP (immu-
nosuppression, allergy to b-lactams, renal
dysfunction, etc.); risk factors for multidrug
resistant pathogens; possibility to switch to the
oral route (sequential treatment); and cost (drug
and monitoring of plasma concentrations). Levo-
ﬂoxacin has been approved by the US Food and
Drug Administration (FDA) for use in the treat-
ment of nosocomial pneumonia, including those
caused by P. aeruginosa [73]. Criteria to be con-
sidered in choosing levoﬂoxacin among other
antimicrobial agents for the empirical and direc-
ted treatment of VAP are as follows:
1 Patients with suspected or conﬁrmed allergy to
b-lactam antibiotics. The majority of antibiotics
used in the treatment of VAP, both empirical
and directed, are b-lactams. Levoﬂoxacin is a
primary antibiotic of choice in this clinical
situation, either as monotherapy (early onset
VAP, no risk of multiresistant pathogens) or
combined with aminoglycosides and ⁄ or gly-
copeptides (late onset VAP, risk for multire-
sistant pathogens). When the drug is used
empirically in monotherapy, it should be
remembered that in patients with successive
re-admissions to hospital and previous
exposure to ﬂuoroquinolones, resistance to
levoﬂoxacin and other quinolones against
P. aeruginosa and Strep. pneumoniae has been
reported [74,75].
2 Patients with impairment of renal function. Levo-
ﬂoxacin is an alternative to aminoglycosides for
empirical treatment with combined antibiotics
in patients with renal dysfunction or at high
risk of renal failure (advanced age, haemo-
dynamic instability). Levoﬂoxacin is the drug of
choice if various nephrotoxic drugs are used
simultaneously, such as vancomycin, ampho-
tericin or cyclosporine.
3 Need to extend antibiotic coverage to intracellular
pathogens. Patients immunocompromised be-
cause of an underlying disease or medications
administered can develop VAP in which a large
list of pathogens can be implicated, including
Legionella pneumophila. Antibiotic coverage for
this pathogen is particularly indicated in
hospitals with L. pneumophila endemicity or if
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L. pneumophila has been identiﬁed in their
water systems. Levoﬂoxacin has an adequate
antibacterial activity against this microorgan-
ism [76] and has demonstrated its usefulness
in circumstances of endemicity or outbreaks
[77].
4 High concentrations in lung tissue and respiratory
secretions. The penetration capacity of levo-
ﬂoxacin in different tissues, especially alveoli
and lung tissue [21–23], is associated with high
concentrations of the antibiotic in the infection
site, as opposed to reduced penetration and low
levels in the lung tissue as with the use of
aminoglycosides [78]. Concentration of levoﬂ-
oxacin in the lung tissue is higher than that
achieved with ciproﬂoxacin, given at the
recommended doses according to the technical
speciﬁcations of the products [79]. For this
reason, although higher inhibitory concentra-
tions for P. aeruginosa are required with this
antibiotic, different pharmacodynamic rela-
tionships are favourable to levoﬂoxacin at
doses of 500 mg ⁄ 12 h, as compared with ci-
proﬂoxacin at doses of 400 mg ⁄ 12 h [79,80].
According to pharmacodynamic indicators,
both antimicrobial agents are equivalent; no
comparative study has been performed to
assess the clinical differences between the
drugs.
5 Possibility of sequential therapy in patients with
satisfactory clinical response. The minimum cri-
teria for the use of sequential therapy include
the availability of both intravenous and oral
formulations of the drug, and demonstration of
sufﬁcient bioavailability to ensure plasma
equivalent concentrations. Levoﬂoxacin is a
new quinolone that meets both requirements,
and multiple studies have shown the useful-
ness of this drug in the treatment of hospital-
ised patients with a low level of severity of
illness [49–57,81]. In the ICU setting, it has been
shown that up to one third of critically ill
patients receiving levoﬂoxacin treatment was
switched to the oral route [34]. These are
patients with less severe clinical conditions in
whom antibiotic treatment was started as
monotherapy. Cost-effectiveness studies of
levoﬂoxacin compared with ceftriaxone for
the treatment of community-acquired pneu-
monia have shown that oral administration of
the drug, when switching from the intravenous
to the oral route was possible, was associated
with lower resource consumption, mostly due
to differences in hospitalisation costs [82,83].
This aspect, however, is less relevant in critic-
ally ill patients admitted to the ICU.
6 Synergistic activity in combined treatment against
P. aeruginosa. In the treatment of infections due
to P. aeruginosa, treatment with a combination
of antibiotics is recommended in order to
increase the antibacterial spectrum of empirical
treatment and to enhance the bactericidal
power of directed therapy [6,19], although up
to the present time there is no evidence for a
greater efﬁcacy of combined antibiotic treat-
ment vs. monotherapy with an active anti-
microbial agent in the treatment of infections
caused by this pathogen [84,85]. Levoﬂoxacin
has shown different rates of synergism when
administered in association with cefepime,
ceftazidime, imipenem, and piperacillin ⁄ tazo-
bactam, indicating that combination with these
antibiotics increases its activity against P. aeru-
ginosa [80,86–88]. Although the MIC of ciproﬂ-
oxacin for P. aeruginosa is four-fold lower than
the MIC of levoﬂoxacin (0.124 mg ⁄L vs.
0.5 mg ⁄L), different studies showed that the
percentage of strains susceptible to both antibi-
otics is very similar [89–92].
7 Lower capacity to induce P. aeruginosa resist-
ance. An in-vitro study demonstrated the
lower capacity to induce resistance against
P. aeruginosa with the association of imipenem
plus levoﬂoxacin [93,94]. Another in-vitro study
with different strains of P. aeruginosa has shown
a higher bactericidal activity of levoﬂoxacin in
comparison with ciproﬂoxacin [95]. These data
support the results of different comparative
clinical studies on the use of quinolones
(ciproﬂoxacin or levoﬂoxacin) in the treatment
of nosocomial pneumonia, in which a lower
tendency towards the selection of resistant
strains was demonstrated when quinolones
were administered [20,64,68].
8 No need to monitor plasma drug concentrations to
ensure effectiveness and to avoid toxicity. Accord-
ing to pharmacodynamic data on levoﬂoxacin,
it is recommended to prescribe doses of
500 mg ⁄ 12 h when the drug is given empiric-
ally for the treatment of nosocomial pneu-
monia, including the potential presence of
P. aeruginosa [31,32], although the new formu-
lation of 750 mg may possibly improve the
pharmacodynamic parameters related to
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greater effectiveness. In contrast to aminogly-
cosides and vancomycin, monitoring plasma
drug concentrations to reduce risks of toxicity
is not necessary.
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